V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220021809 | 220007037 | 1.56 | null | Curative (C) | 2019-02-08 | 2019-02-08 | Alemtuz+Fludara+Melphalan RIC MUD | 02 | null | 220026961 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220021811 | 220007066 | 1.78 | 74.3 | Curative (C) | 2018-12-26 | 2018-12-26 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 220027042 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220021812 | 220007091 | 1.67 | 77.5 | Curative (C) | 2017-04-02 | 2017-04-07 | BOSUTINIB | N | N | 220027179 | BOSUTINIB |
| 220021813 | 220007177 | 1.67 | null | null | 2016-10-26 | 2017-02-10 | Cyclophosphamide+Fludara+TBI Allo | 2 | N | 220027553 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220021814 | 220007207 | 1.54 | 0 | Curative (C) | 2016-04-07 | 2016-07-28 | IDARUBICIN + TRETINOIN | 2 | N | 220027665 | IDARUBICIN + TRETINOIN |
| 220021815 | 220007215 | 1.52 | 60.3 | Curative (C) | 2015-05-05 | 2015-05-11 | RUXOLITINIB | 02 | N | 220027691 | RUXOLITINIB |
| 220021816 | 220007217 | 1.66 | 75 | Curative (C) | 2016-07-15 | 2016-07-15 | AML Int Guide ADE 8+3+5 (2) | N | N | 220027703 | ADE |
| 220021817 | 220017625 | 1.7 | null | Curative (C) | 2016-06-06 | 2016-06-13 | RUXOLITINIB | 2 | N | 220027940 | RUXOLITINIB |
| 220021818 | 220007298 | null | 70.8 | Curative (C) | 2017-10-02 | 2017-10-02 | BOSUTINIB | Y | N | 220028118 | BOSUTINIB |
| 220021819 | 220014018 | 1.94 | 145.5 | Curative (C) | 2000-10-26 | 2013-10-24 | Triple Intrathecal | N | N | 220028136 | TRIPLE INTRATHECAL |
| 220021820 | 220007320 | 1.86 | null | null | 2015-01-23 | 2016-08-11 | Methotrexate intrathecal | Y | null | 220028203 | METHOTREXATE INTRATHECAL |
| 220021821 | 220007322 | 1.66 | 58.7 | Curative (C) | 2017-11-07 | 2017-11-14 | Triple Intrathecal | 02 | N | 220028206 | TRIPLE INTRATHECAL |
| 220021822 | 220007339 | null | 83.1 | Curative (C) | 2018-06-28 | 2018-06-29 | Cyclophosphamide+Fludara+TBI Allo | 99 | N | 220028292 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220021823 | 220014051 | null | 83.2 | Palliative (P) | 2014-07-16 | 2014-07-21 | BOSUTINIB | null | null | 220028341 | BOSUTINIB |
| 220021824 | 220014058 | 1.66 | 58 | Adjuvant (A) | 2014-11-12 | 2015-04-08 | ATG + Busulfan + Fludarabine | N | N | 220028396 | ATG + BUSULFAN + FLUDARABINE |
| 220021825 | 220007381 | 1.69 | 74 | Disease modification (D) | 2014-05-23 | 2014-05-23 | CYCLOPHOSPHAMIDE + FLUDARABINE | 2 | N | 220028490 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220021826 | 220014106 | 1.62 | 39.8 | Disease modification (D) | 2018-07-10 | 2018-07-14 | FLAG | 2 | N | 220028812 | FLAG |
| 220021827 | 220007511 | 1.72 | 85.5 | Disease modification (D) | 2013-08-03 | 2015-03-02 | RUXOLITINIB | N | N | 220028990 | RUXOLITINIB |
| 220021828 | 220017706 | 1.72 | 95.7 | Curative (C) | 2018-03-16 | 2018-03-28 | AML Int Guide ADE 10+3+5 (1) | N | N | 220028999 | ADE |
| 220021829 | 220007549 | 1.61 | 84.8 | Disease modification (D) | null | 2018-06-29 | Methotrexate intrathecal | N | null | 220029118 | METHOTREXATE INTRATHECAL |
| 220021830 | 220007556 | 1.88 | 74 | Disease modification (D) | 2015-09-16 | 2016-06-21 | Cyclophosphamide+Fludara+TBI Allo | N | N | 220029134 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220021832 | 220007595 | 1.7 | 68.8 | Disease modification (D) | 2018-11-23 | 2019-04-21 | AML16 DA 3+8 | N | N | 220029327 | AML16 TRIAL |
| 220021834 | 220017746 | 1.59 | 85 | Curative (C) | 2014-07-03 | 2014-07-11 | RUXOLITINIB | N | null | 220029445 | RUXOLITINIB |
| 220021835 | 220007639 | 1.65 | 66 | Curative (C) | 2014-07-16 | 2016-08-06 | RUXOLITINIB | Y | N | 220029470 | RUXOLITINIB |
| 220021836 | 220007694 | 1.88 | 68.9 | Palliative (P) | 2015-02-10 | 2015-03-28 | Idarubicin+Tretinoin Spanish Crse2 | Y | N | 220029672 | IDARUBICIN + TRETINOIN |
| 220021837 | 220007747 | 1.65 | 76 | null | 2016-06-21 | 2016-07-16 | ATG + Busulfan + Fludarabine | N | null | 220029817 | ATG + BUSULFAN + FLUDARABINE |
| 220021838 | 220019770 | 1.56 | 54 | Curative (C) | 2016-11-18 | 2016-11-23 | Idarubicin+Tretinoin Spanish Crse2 | N | N | 220030114 | IDARUBICIN + TRETINOIN |
| 220021839 | 220007840 | 0.84 | 68.8 | Disease modification (D) | 2015-12-17 | 2016-01-02 | Methotrexate intrathecal | 99 | N | 220030144 | METHOTREXATE INTRATHECAL |
| 220021840 | 220007848 | 1.7 | 102 | Curative (C) | 2019-04-16 | 2019-04-16 | CYCLOPHOSPHAMIDE + FLUDARABINE | N | N | 220030148 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220021841 | 220007875 | 1.63 | 71 | Curative (C) | 2018-02-14 | 2018-02-14 | IDARUBICIN + TRETINOIN | N | N | 220030225 | IDARUBICIN + TRETINOIN |
| 220021843 | 220007929 | null | 74 | Curative (C) | 2014-05-29 | 2014-07-07 | ATG + Busulfan + Fludarabine | Y | N | 220030353 | ATG + BUSULFAN + FLUDARABINE |
| 220021844 | 220007946 | null | 114 | Curative (C) | 2018-01-21 | 2018-02-22 | AML Int Guide ADE 8+3+5 (2) | 02 | N | 220030435 | ADE |
| 220021845 | 220007961 | 1.63 | null | Disease modification (D) | 2015-08-06 | 2015-08-06 | CYCLOPHOSPHAMIDE | 2 | N | 220030471 | CYCLOPHOSPHAMIDE |
| 220021846 | 220007964 | null | 76.9 | Not known (9) | 2018-10-01 | 2018-10-09 | AML16 DA 3+10 | N | N | 220030475 | AML16 TRIAL |
| 220021847 | 220014372 | 1.9 | 80.4 | Curative (C) | 2017-12-23 | 2018-04-14 | Idarubicin+Tretinoin Spanish Crse2 | N | null | 220030478 | IDARUBICIN + TRETINOIN |
| 220021848 | 220007982 | 1.66 | 59.3 | Palliative (P) | 2013-12-28 | 2014-06-04 | Fludarabine + Melphalan RIC Allo | null | null | 220030497 | METHOTREXATE |
| 220021849 | 220007997 | 1.69 | null | Curative (C) | null | 2015-06-21 | UKALL14- Intens/CNS Proph | N | N | 220030530 | CLOFARABINE + CYTARABINE |
| 220021850 | 220014398 | null | 84.5 | Curative (C) | 2016-11-25 | 2017-01-19 | CISPLATIN + GEMCITABINE | N | N | 220030624 | ECX |
| 220021851 | 220008036 | null | 100.8 | Palliative (P) | 2015-05-24 | 2015-05-24 | Alemtuzumab cond (RI ALLO CAMP100) | null | null | 220030630 | ALEMTUZUMAB |
| 220021852 | 220008089 | null | null | Curative (C) | 2014-11-09 | 2014-11-12 | Cytarabine intrathecal | 02 | N | 220030766 | CYTARABINE INTRATHECAL |
| 220021853 | 220022364 | 1.63 | 99.1 | Adjuvant (A) | 2017-12-07 | 2018-03-18 | PONATINIB | 2 | N | 220030779 | CISPLATIN + GEMCITABINE |
| 220021855 | 220008145 | null | 64 | Curative (C) | null | 2019-03-24 | Mitoxantrone | N | N | 220030955 | MITOXANTRONE |
| 220021857 | 220008155 | 1.85 | 54 | Curative (C) | 2014-09-18 | 2014-09-23 | Alemtuzumab cond (RI ALLO CAMP100) | 02 | N | 220030962 | ALEMTUZUMAB |
| 220021859 | 220008171 | 1.78 | 93 | Curative (C) | null | 2013-11-07 | Irinotecan + Modified De Gramont | null | null | 220031002 | OXALIPLATIN + MDG |
| 220021860 | 220017893 | 1.76 | null | Curative (C) | 2018-07-03 | 2018-07-03 | Carboplatin + Etoposide iv&po | 02 | N | 220031027 | CARBOPLATIN + ETOPOSIDE |
| 220021862 | 220008241 | 1.55 | 57 | Curative (C) | 2015-05-04 | 2015-05-06 | Alemtuzumab cond (RI ALLO CAMP100) | 2 | N | 220031302 | ALEMTUZUMAB |
| 220021863 | 220008254 | 1.94 | 85 | Curative (C) | 2015-11-11 | 2015-11-11 | PONATINIB | null | null | 220031392 | CLOFARABINE + CYTARABINE |
| 220021864 | 220008263 | 1.75 | 67.7 | Curative (C) | 2017-11-26 | 2018-03-18 | UKALL14- Maintenance | N | N | 220031415 | DOCETAXEL |
| 220021865 | 220014519 | 1.62 | 81 | Curative (C) | 2015-01-08 | 2015-01-11 | Carboplatin + Etoposide IV 3 day | 02 | N | 220031606 | CARBOPLATIN + ETOPOSIDE |
| 220021866 | 220008323 | 1.77 | 84.45 | Palliative (P) | 2013-09-10 | 2013-10-01 | FLUDARABINE + MELPHALAN | N | N | 220031607 | PONATINIB |